AI
EDIT icon

Alphabet Inc’s Editas Medicine EDIT Stock Holding History

Alphabet Inc’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-256,410
Closed -$6.26M – 3
2016
Q2 		$6.26M Hold
256,410
– – 2.98% 2
2016
Q1 		$8.86M Buy
+256,410
New +$6.74M 3.65% 3

Other funds holding EDIT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVMCV
Polaris Venture Management Co VI Boston, Massachusetts $43.1M AUM 78.12% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Alphabet Inc's EDIT Position: Q3 2016 in Review

Alphabet Inc sold out of Editas Medicine (EDIT) in Q3 2016, closing a stake of 256,410 shares — an estimated $6.26M sold.

Alphabet Inc first reported a position in EDIT in Q1 2016 and held it in 2 quarters. The position peaked at $8.86M in Q1 2016. 75 funds tracked by Wall St. Rank hold EDIT as of Q3 2016.

  • Alphabet Inc reported no remaining Editas Medicine position as of Q3 2016 after selling out during the quarter.
  • Alphabet Inc sold 256,410 Editas Medicine shares in Q3 2016, an estimated $6.26M.
  • Alphabet Inc first reported a position in Editas Medicine in Q1 2016 and held it in 2 quarters.
  • Alphabet Inc's Editas Medicine position peaked at $8.86M in Q1 2016.
  • 75 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2016.

Based on Alphabet Inc's 13F filing for Q3 2016, filed 15 Nov 2022.